NOL55 inhibitors are a class of chemical compounds that specifically target and inhibit the activity of Nucleolar Protein 55 (NOL55), a nucleolar protein involved in ribosome biogenesis and RNA processing. NOL55 plays a crucial role in the maturation of ribosomal RNA (rRNA) and is essential for the assembly of ribosomal subunits, which are necessary for protein synthesis in eukaryotic cells. By inhibiting NOL55, these compounds interfere with nucleolar functions, ultimately impacting the production of ribosomes, a process that is highly regulated and crucial for cellular growth and proliferation. The mechanism of action typically involves the disruption of NOL55's interactions with other nucleolar components, such as RNA and ribosomal precursors, leading to downstream effects on nucleolar architecture and ribosome assembly pathways.
Chemically, NOL55 inhibitors belong to diverse structural families, often characterized by their ability to bind selectively to NOL55 or associated nucleolar structures. These compounds may include small molecules, peptides, or nucleic acid analogs designed to disrupt NOL55 activity through direct binding or indirect modulation of its regulatory pathways. Researchers often study the effects of NOL55 inhibitors in cell models to understand their impact on ribosomal synthesis and cellular function, especially in relation to nucleolar stress and the cell cycle. These inhibitors are valuable tools for dissecting the molecular mechanisms of ribosome biogenesis and nucleolar function, providing insights into fundamental aspects of cell biology.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
Actinomycin D may inhibit P3H4 expression by disrupting RNA polymerase activity, leading to reduced transcription of P3H4 mRNA. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
Cycloheximide inhibits protein synthesis, potentially reducing P3H4 levels and its subsequent function in collagen biosynthesis. | ||||||
Puromycin | 53-79-2 | sc-205821 sc-205821A | 10 mg 25 mg | $163.00 $316.00 | 436 | |
Puromycin integrates into protein chains during synthesis, potentially decreasing P3H4 levels and its involvement in collagen formation. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $97.00 $254.00 | 36 | |
Anisomycin may inhibit P3H4 expression by interfering with protein synthesis, leading to reduced levels of functional P3H4 enzyme. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $76.00 $216.00 | 101 | |
Cisplatin may modulate transcription factors involved in P3H4 expression, potentially reducing the production of P3H4 protein. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $32.00 $170.00 $385.00 | 63 | |
Etoposide can impact P3H4 expression through its effects on DNA topoisomerase II, potentially altering the transcription of P3H4. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $57.00 $182.00 $92.00 | 21 | |
Camptothecin may impact P3H4 expression by affecting DNA topoisomerase I, potentially altering the transcription of P3H4. | ||||||
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $173.00 $418.00 | 43 | |
Doxorubicin may affect P3H4 expression through its impact on DNA and associated cellular stress responses, potentially altering P3H4 expression. | ||||||
Ellipticine | 519-23-3 | sc-200878 sc-200878A | 10 mg 50 mg | $142.00 $558.00 | 4 | |
Ellipticine might impact P3H4 expression through its effects on DNA and potential alterations in the expression of P3H4. | ||||||
Mitomycin C | 50-07-7 | sc-3514A sc-3514 sc-3514B | 2 mg 5 mg 10 mg | $65.00 $99.00 $140.00 | 85 | |
Mitomycin C could affect P3H4 expression by causing DNA crosslinking, potentially leading to altered P3H4 expression levels. | ||||||